Search

Oppenheimer raised the firm's price target on United Therapeutics to $600 from $575 and keeps an Outperform rating on the shares following quarterly results. The firm says 'robust' Q3 financials [...]

Ladenburg raised the firm's price target on United Therapeutics to $344 from $319 and keeps a Buy rating on the shares following the Q3 report. The firm expects the growth [...]

Scotiabank initiated coverage of Liquidia (LQDA) with an Outperform rating and $30 price target. As Liquidia's legal battle with competitor United Therapeutics (UTHR) over Tyvaso comes to a close, the [...]

As previously reported, LifeSci Capital initiated coverage of Liquidia with an Outperform rating and $30 price target. The commercial-stage biotechnology company's pipeline is focused on innovative delivery mechanisms for treprostinil [...]

Liquidia Corporation announced that the United States District Court for the District of New Jersey has found that the interference by United Therapeutics Corporation with the launch of generic Treprostinil [...]

Oppenheimer raised the firm's price target on United Therapeutics to $575 from $400 and keeps an Outperform rating on the shares after hosting two key opinion leaders, or KOLs, for [...]

H.C. Wainwright lowered the firm's price target on Liquidia (LQDA) to $29 from $32 and keeps a Buy rating on the shares. The analyst believes United Therapeutics (UTHR) effectively delayed [...]

Liquidia Corporation, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced that the US Food and Drug Administration (FDA) has granted tentative approval of Yutrepia (treprostinil) [...]

Wells Fargo analyst Tiago Fauth raised the firm's price target on Insmed to $85 from $77 and keeps an Overweight rating on the shares. The firm thinks Treprostinil Palmitil Inhalation [...]

Reports Q2 revenue $3.66M, consensus $9.45M. Cash and cash equivalents totaled $133.1M as of June 30 compared to $83.7M as of December 31, 2023. The company said, 'Revenue related primarily [...]

Reports Q1 revenue $2.97M, consensus $4.39M. Cash and cash equivalents totaled $157.9M as of March 31, compared to $83.7M as of December 31, 2023. Roger Jeffs, Liquidia's CEO, said: 'We [...]

Barclays raised the firm's price target on Insmed to $40 from $37 and keeps an Overweight rating on the shares. The analyst sees 'compelling reasons to be optimistic' on treprostinil [...]

2024 JAN 6 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on treprostinil therapy is the subject of a new report. [...]

2023 NOV 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- DelveInsight's Sarcoidosis Market Insights report includes a comprehensive understanding of current treatment [...]

North Carolina continues to gain prominence as a major life sciences state with investments from both large pharmaceutical companies and innovative new businesses and startups. Clusters of manufacturers have developed [...]

Reports Q1 revenue $4.5M, consensus $3.95M. Roger Jeffs, CEO, said: 'We have heard from the physician community about the increasing demand for inhaled treprostinil to treat both pulmonary arterial hypertension [...]

Ladenburg analyst Matthew Kaplan lowered the firm's price target on United Therapeutics to $256 from $285 and keeps a Buy rating on the shares post the Q1 results. The decreased [...]

Byline: Moneylife Digital Team The trends of the major indices in the course of the week's trading are given in the table below: On Monday, 1849 stocks advanced, 1737 declined [...]

Byline: Moneylife Digital Team On Friday, 1477 stocks advanced, 1985 declined and 122 remained unchanged on the Bombay Stock Exchange (BSE), with an advance decline ratio of 0.74, indicating a [...]

Dr. Reddy's announced the launch of Treprostinil Injection in the U.S. market, a therapeutic equivalent generic version of Remodulin Injection, approved by the [...]

2023 MAR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on biomedicine have been presented. According to news reporting originating [...]

United Therapeutics Corporation, a public benefit corporation, announced that a preliminary analysis of the EXPEDITE study in patients suffering from World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH)demonstrated [...]

Wedbush analyst Andreas Argyrides assumed coverage of United Therapeutics with an Outperform rating and $263 price target. The analyst considers United Therapeutics an opportunity to invest in proven growth through [...]

United Therapeutics Corporation (UTHR) announced that the United States District Court for the District of Delaware issued an opinion in the pending litigation concerning United Therapeutics' U.S. patents 9,593,066 and [...]

BofA analyst Greg Harrison notes that Liquidia (LQDA) shares are under significant pressure after a decision from the U.S. District Court denying Liquidia's request to stay a decision on the [...]

Reports Q2 revenue $466.9M, consensus $461.06M. 'I'm extraordinarily pleased with our business performance this past quarter,' said CEO Martine Rothblatt. 'The FDA's approval of our Tyvaso DPI medicine and recent [...]

Liquidia announced the publication of clinical data from the completed INSPIRE study evaluating YUTREPIA inhalation powder, formerly known as LIQ861, in patients with pulmonary arterial hypertension in the journal Pulmonary [...]

Ladenburg analyst Matt Kaplan initiated coverage of Liquidia Technologies (LQDA) with a Buy rating and $15 price target. Lead asset Yutrepia is a dry powder inhaler of treprostinil being developed [...]

BTIG analyst Julian Harrison raised the firm's price target on Liquidia Technologies to $17 from $14 and keeps a Buy rating on the shares. The analyst cites the ruling by [...]

2022 JUN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Drugs and Therapies - Treprostinil Therapy have been presented. [...]

The Food and Drug Administration (FDA) has approved Tyvaso DPI™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial [...]

Wedbush analyst Liana Moussatos raised the firm's price target on United Therapeutics to $263 from $236 and keeps an Outperform rating on the shares after the FDA approved Tyvaso DPI [...]

MannKind (MNKD) celebrated that the U.S. FDA has approved United Therapeutics' (UTHR) Tyvaso DPI inhalation powder for the treatment of patients with pulmonary arterial hypertension and pulmonary hypertension associated with [...]

United Therapeutics announced that the U.S. FDA has approved Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve [...]

Reports Q1 revenue $461.9M, consensus $420.02M. 'The hard work and dedication of our Unitherians has resulted in double-digit percentage revenue growth year-over-year for Tyvaso, Orenitram, Unituxin, and our total treprostinil [...]

ALAN AUERBACH Chief Executive and Chairman Puma Biotechnology Inc. THE LATEST: Earlier this year, Auerbach and Puma Biotechnology Inc. were embroiled in a securities class-action lawsuit over the effect on [...]

Pharmaceuticals Analyst Yang and Biotechnology Analyst Howerton discuss the upcoming patent trial between United Therapeutics (UTHR) and Liquidia Corp (LQDA) on Inhaled Treprostinil on an Analyst/Industry conference call to be [...]

The Food and Drug Administration (FDA) has granted tentative approval for Yutrepia (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in adults with [...]

Reports Q3 revenue $3.18M, consensus $2.74M. Damian deGoa, Liquidia's CEO, said: 'We had another productive quarter. Sales performance of Treprostinil Injection was ahead of target. The initial uptake has been [...]

Reports Q3 revenue $444.7M, consensus $421.45M. Net product sales from treprostinil-based products grew by $46.1M in Q3. 'Our momentum continues with growing patient use of our medicines, which are delivered [...]

United Therapeutics Corporation announced an update on the US Food and Drug Administration (FDA) review of the new drug application (NDA) for Tyvaso DPI, for the treatment of pulmonary arterial [...]

The Food and Drug Administration has issued a Complete Response Letter (CRL) to United Therapeutics Corporation regarding the New Drug Application for Tyvaso DPI™ (inhaled treprostinil) for the treatment of [...]

MannKind (MNKD) has learned that the FDA issued a complete response to United Therapeutics (UTHR) regarding the New Drug Application for Tyvaso DPI for the treatment of pulmonary arterial hypertension [...]

United Therapeutics presented new clinical data from the BREEZE study evaluating Tyvaso DPI in patients with pulmonary arterial hypertension, or PAH, at the European Respiratory Society, or ERS, International Congress. [...]

Reports Q2 revenue $3.376M, consensus $1.72M. Damian deGoa, Liquidia's Chief Executive Officer, said: 'We continue to execute on our corporate priorities and strengthen the company's position. We are excited to [...]

Reports Q2 revenue $446.5M, consensus $378.75M. 'We are pleased to continue our expansion into new indications outside of WHO Group 1 PAH with strong Tyvaso financial results, and with patient [...]

Argus analyst Jasper Hellweg upgraded United Therapeutics to Buy from Hold with a $205 price target. Shares have pulled back from their recent highs above $210 and offer investors a [...]

2021 JUN 26 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- United Therapeutics Corporation (Nasdaq: UTHR) announced that it is pursuing additional claims [...]

United Therapeutics Corporation announced that the US Food and Drug Administration (FDA) accepted for priority review the New Drug Application (NDA) for Tyvaso DPI (inhaled treprostinil) for the treatment of [...]

United Therapeutics (UTHR) announced that it is pursuing additional claims for trade secret misappropriation against Liquidia Technologies, a subsidiary of Liquidia (LQDA) and a former United Therapeutics employee who later [...]